Y-Intercept (HK)’s Charles River Laboratories CRL Stock Holding History

Y-Intercept (HK)’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1,245	Closed	-$282K	–	1660
2026 Q2	$282K	Sell	1,245 -4,669	-79%	-$831K	0.01%	1484
2026 Q1	$1.02M	Sell	5,914 -3,454	-37%	-$640K	0.02%	1021
2025 Q4	$1.87M	Buy	9,368 +1,842	+24%	+$334K	0.04%	657
2025 Q3	$1.18M	Buy	+7,526	New	+$1.2M	0.03%	900
2025 Q2	–	Sell	-3,760	Closed	-$566K	–	1686
2025 Q1	$566K	Buy	+3,760	New	+$630K	0.04%	645
2023 Q3	–	Sell	-10,712	Closed	-$2.25M	–	1136
2023 Q2	$2.25M	Buy	10,712 +8,293	+343%	+$1.65M	0.24%	94
2023 Q1	$488K	Buy	+2,419	New	+$548K	0.06%	544
2022 Q3	–	Sell	-5,558	Closed	-$1.19M	–	1017
2022 Q2	$1.19M	Buy	5,558 +4,727	+569%	+$1.16M	0.16%	187
2022 Q1	$236K	Buy	+831	New	+$256K	0.05%	547

Other funds holding CRL

Cooke & Bieler Philadelphia, Pennsylvania $6.36B AUM 0.55% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Confluence Investment Management St. Louis, Missouri $5.97B AUM 5.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Lawson Kroeker Investment Management Omaha, Nebraska $360M AUM 21.88% 1-Year Est. Return

Midwest Trust Overland Park, Kansas $8.99B AUM 21.14% 1-Year Est. Return

Sendero Wealth Management San Antonio, Texas $1B AUM 21.35% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12.3B AUM 33.99% 1-Year Est. Return

Y-Intercept (HK)'s CRL Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Charles River Laboratories (CRL) in Q3 2026, closing a stake of 1,245 shares — an estimated $282K sold.

Y-Intercept (HK) first reported a position in CRL in Q1 2022 and held it in 9 quarters. The position peaked at $2.25M in Q2 2023. 104 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

Y-Intercept (HK) reported no remaining Charles River Laboratories position as of Q3 2026 after selling out during the quarter.
Y-Intercept (HK) sold 1,245 Charles River Laboratories shares in Q3 2026, an estimated $282K.
Y-Intercept (HK) first reported a position in Charles River Laboratories in Q1 2022 and held it in 9 quarters.
Y-Intercept (HK)'s Charles River Laboratories position peaked at $2.25M in Q2 2023.
104 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.